Frank McCormick, PhD, FRS

University of Birmingham, England, B.Sc., 1972, Biochemistry
University of Cambridge, England, Ph.D., 1975, Biochemistry

• 1975-78
  Professor Seymour S. Cohen, State University of New York at Stony Brook (Post Doctoral Fellow)
• 1978-81
  Dr. Alan Smith, Imperial Cancer Research Fund, London (Post Doctoral Fellow)
• 1981-90
  Cetus Corporation (Director of Molecular Biology)
• 1990-91
  Cetus Corporation (Vice President, Research)
• 1991-92
  Chiron Corporation (Vice President, Research)
• 1992-96
  Onyx Pharmaceuticals (Founder, Chief Scientific Officer)
• 1996-present
  Fellow of the Royal Society
• 1997-2009
  University of California, San Francisco, Cancer Research Institute (Director)
• 1997-present
  University of California, San Francisco, Dept. of Microbiology & Immunology (Professor)
• 1997-
  University of California, San Francisco, Cancer Center, (Director, Associate Dean)

• 1996
  Fellow of the Royal Society
• 2002
  Bristol Myers Squibb Unrestricted Cancer Research Grant
• 2002
  AACR - G.H.A. Clowes Memorial Award
• 2002
  Novartis Drew Award in Biomedical Research
• 2003
  University of Chicago, Cancer Research Center, Shubitz Award
• 2005
  Institute of Medicine
• 2010
  ASCO Science of Oncology Award

• (from 270 peer-reviewed publications)
• McCormick F. Cancer-specific viruses and the development of ONYX-015. Cancer Biol Ther 2003;2:S157 60.
• O'Shea C, Johnson L, Bagus B, Choi S, Nicholas C, Shen A, Boyle L, Pandey K, Soria C, Kunich J, Shen Y, Habets G, Ginzinger D, McCormick F. Late viral RNA export, rather than p53 inactivation, determines ONYX-015 tumor selectivity. Cancer Cell 2004;6:611-23.
• O’Shea C, Klupsch K, Choi S, Bagus B, Soria C, Shen J, McCormick F, Stokoe D. Adenoviral proteins mimic nutrient/ growth signals to activate the mTOR pathway for viral replication. EMBO J 2005;24:1211 21.
• Reid TR, Freeman S, Post L, McCormick F, Sze DY. Effects of ONYX-015 among metastatic colorectal cancer patients that have failed prior treatment with 5-FU/leucoforin. Cancer Gene Ther 2005;12:673-81.
• O’Shea C, Choi S, Bagus B, McCormick F. Heat shock phenocopies E1B-55K late functions and selectively sensitizes refractory tumor cells to ONYX-015 oncolytic viral therapy. Cancer Cell 2005;8:61 74.
• Macrae M, Neve RM, Rodriguez-Viciana P, Haqq C, Yeh J, Chen C, Gray JW, McCormick F. A conditional feedback loop regulates Ras activity through EphA2. Cancer Cell 2005;8:111-8.
• Oda, K., Stokoe, D., Taketani, Y., McCormick, F. 2005. High frequency of co-existent mutations of PIK3CA and PTEN genes in endometrial carcinoma. Cancer Research 65: 10669-73.
• Neve, R. M., Chin, K., Fridlyand, J., Yeh, J., Baehner, F.L., Fevr, T., Clark, L., Bayani, N., Coppe JP, Tong, F., Speed, T., Spellman, P.T., DeVries, S., Lapuk, A., Wang, N.J., Kuo, W.L., Stilwell, J.L., Pinkel, D., Albertson, D.G., Waldman, F.M., McCormick, F., Dickson, R.B., Johnson, M.D., Lippman, M., Ethier, S., Gazdar, A., Gray, J.W. 2006. A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes. Cancer Cell 10:515-27. Rodriguez-Viciana, P., Oses-Prieto, J., Burlingame, A., Fried, M., McCormick, F. 2006. A phosphate holoenzyme comprised of shoc2/sur8 and the catalytic subunit of pp1 functions as an M-Ras effector to modulate Raf activity. Molecular Cell 22:217-30
• Rodriguez-Viciana P, Tetsu O, Tidyman WE, Estep AL, Conger BA, Cruz MS, McCormick F, Rauen KA. Germline mutations in genes within the MAPK pathway cause radio-facio-cutaneous syndrome. Science 2006;311:1287-90.
• Rodriguez-Viciana P, McCormick F. Ras ubiquitination: coupling spatial sorting and signal transmission. Cancer Cell 2006;9:243-4.
• Lee SH, McCormick F. p97/DAP5 is a ribosome-associated factor that facilitates protein synthesis and cell proliferation by modulating the synthesis of cell cycle proteins. EMBO J 2006;25:4008-19.
• Estep A.L., Palmer, C., McCormick, F., Rauen, K.A. 2008. Mutation analysis of BRAF, MEK1 and MEK2 in 15 Ovarian Cancer Cell Lines: Implications for Therapy. PLoS ONE 2:e1279. PMCID: PMC2093994.
• Oda, K., Okada, J., Timmerman, L., Rodriguez-Vicana, P., Stokoe, D., Shoji, K., Taketani, Y., Kuramoto, H., Knight, Z., Shokat, K., McCormick, F. 2008. PIK3CA cooperate with other PI3K pathway mutations to effect oncogenic transformation. Cancer Research 2008 Oct 1:68(19):8127-36. PMCID: PMC18829572.